Our leaders

LinkedIn

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 190 papers and is an inventor of over 250 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB; merged with Cartesian Therapeutics NASDAQ: RNAC), Tarveda Therapeutics and PrognomiQ, where he serves as Chair of Board. Omid is a recipient of the 2023 Mustafa Prize and the 2013 RUSNANOPRIZE for his work on nanomaterial surface modification. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management. Chairman of the Board

David R. Horn is the Chief Financial Officer for Seer. Prior to joining Seer, Mr. Horn worked at Morgan Stanley for over 20 years, where he served as a Managing Director in the firm’s Global Healthcare Group within the Investment Banking Department. Mr. Horn was responsible for Morgan Stanley’s global Life Science Tools and Diagnostics practice and oversaw the Western Region Healthcare practice. In addition, Mr. Horn previously spent time working in the medical device and life science sectors where he served as Vice President of Business Development at RITA Medical Systems and, prior to that, in the same role at Chemdex Corporation. Mr. Horn holds a Bachelor of Arts from Princeton University and an MBA from the Stanford University Graduate School of Business.

Anthony Bazarko is Chief Commercial Officer at Seer, where he leads global commercial strategy and execution. Prior to joining Seer, he served as President and Chief Executive Officer of Biologos from 2022 to 2025, guiding the company’s strategic and operational transformation and its acquisition by Ampersand Capital Partners. Previously, he was Chief Commercial Officer at Specific Diagnostics, where he built and executed a global go-to-market strategy that culminated in the company’s acquisition by bioMérieux. Earlier in his career, Mr. Bazarko held leadership roles at Danaher’s Leica Biosystems, serving as Vice President of Commercial Development for the Americas, and at Roche Diagnostics, where he led the life science tools commercial business and was part of the strategic affairs organization for RDC North America. Mr. Bazarko holds a Bachelor of Science from Indiana University Bloomington and a Master of Business Administration from Northwestern University, Kellogg School of Management.

Marissa is our Chief People Officer. Prior to joining Seer, Marissa was Vice President of Human Resources of CareDx where she helped to grow the business from 70 million and 140 employees to over 190 million and 500 employees in a little over 3 years. Marissa brings over 20 years of human resources leadership experience to Seer, holding various HR roles with increasing responsibility in the biotech industry at companies such as Metabiota and DuPont Industrial Biosciences. Marissa holds Master’s degrees in HR Design and Psychology from Claremont Graduate University. In addition, she holds a Bachelor’s in Social Sciences from California Polytechnic State University, San Luis Obispo.

Serafim Batzoglou is Chief Data Officer at Seer. Prior to joining Seer, Serafim served as Chief Data Officer at Insitro, leading machine learning and data science in their approach to drug discovery. Prior to Insitro, he served as VP of Applied and Computational Biology at Illumina, leading research and technology development of AI and molecular assays for making genomic data more interpretable in human health. Serafim was a co-founder of DNAnexus Inc. in 2009. He spent 15 years at Stanford University as Professor of Computer Science and Biomedical Data Sciences, and as a member of the Stanford AI Lab (SAIL). He has received numerous awards and distinctions, including Top Young Technology Innovator in MIT Technology Review in 2003, the inaugural Innovator Award by the International Society for Computational Biology (ISCB) in 2016, and Fellow of the ISCB in 2020. Serafim has served on several scientific advisory boards including those of 23andMe, NextBio, DNAnexus, Eve Biomedical, Genapsys and Moleculo. Serafim holds a PhD in Computer Science from Massachusetts Institute of Technology.

Kenny is Chief Operations and Product Officer at Seer. Prior to Seer, Kenny was VP, Factory of the Future at Illumina. Kenny’s responsibilities included Global Manufacturing Strategy, Operational Excellence, Automation, Operations Technology, Data Analytics and Process Development, and Transfer for Consumables New Product Introduction. Prior to Illumina, Kenny was Vice President, Global Operations for the Genetic Sciences (GSD) and Clinical Next-Gen Sequencing (CSD) Divisions of Thermo Fisher Scientific, supporting annual revenue of $4B per year. Kenny also spent a number of years with increasing operational responsibility at Applied Biosystems and Life Technologies, both in the UK and the US, and had Operational responsibilities for the TaqMan, AmpliSeq, HID and Ion Torrent product lines. Kenny has a PhD in Bioorganic Chemistry from Aston University, with a focus on solid-phase oligonucleotide synthesis.

Marty is Senior Vice President of Development at Seer. Prior to Seer, Marty was at Talis Biomedical Corporation where he served most recently as Sr. VP, Operations and prior to that, Sr. VP Research & Development.  Before joining Talis, he was Chief Operating Office at Gen9, a synthetic biology startup.  Marty was at Affymetrix from 1993 to 2010 in roles of increasing responsibility, where he established and oversaw the company’s first wafer scale manufacturing facility, and also as Sr. VP R&D, where he had responsibility for the commercialization of numerous GeneChip® products ranging from new gene expression, genotyping or cytogenetic detection arrays to the launch of the GeneTitan® and GeneAtlas® platforms. Marty holds a PhD in Chemistry from the University of California at San Diego with a focus on physical organometallic chemistry.

Asim Siddiqui has a long history of leading research programs across academia and industry. In industry, the domains he has worked in include drug discovery (Chief Technology Officer at NuMedii), prenatal diagnostics (Vice President of Product Development at Natera) and genomics tools (Director of Bioinformatics at Life Technologies). In academia, he was Bioinformatics Group Leader at the BC Genome Sciences Centre and involved in a number of large-scale genomics projects including the rat genome and poplar genome. Asim has been an author over 40 peer-reviewed publications and holds a doctorate in Bioinformatics from Oxford University, and a degree in Physics from Cambridge University.